News & Updates

Erenumab proves to be effective at lowering the number of monthly migraine days in Asian patients with chronic migraine while having a favourable safety profile, according to the results of DRAGON study.

Weekly somapacitan is noninferior to daily growth hormone (GH) in terms of height velocity (HV), with comparable safety and mean insulin-like growth factor-1 standard deviation score (IGF-1 SDS) levels in treatment-naïve children with growth hormone deficiency (GHD), a study has shown.

Low intake of dietary choline may increase the risk of incident dementia and Alzheimer’s disease (AD), a recent study has found.

There appears to be no longitudinal association between hair cortisol and cortisone levels with dementia and various measures of cognitive function, a recent study has found.

Itraconazole appears to be effective in the treatment of patients with tinea corporis/cruris (TCC) or ringworm of the body, as shown in a study. However, the treatment duration needs to be longer and, even with successful treatment, many patients experience relapse.

Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15^th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.